| 1 | Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1alone in locally advanced gastric cancer(RESCUE-GC study): a protocol for a phase Ⅲ randomized controlled trial显示文摘Background:The ACTS-GC study had shown postoperative adjuvant therapy with S-1 improved survival of patients with locally advanced gastric cancer.Addition of oxaliplatin to S-1 is considered to be acceptable as one of the treatment options for gastric cancer patients after radical gastrectomy with D2 lymph node excision.Methods:We have commenced a randomized phase III trial in December 2016 to evaluate S-1 plus oxaliplatin compared with S-1 alone in the adjuvant setting for locally advanced gastric cancer.A total of 564 patients will be accrued from 13 Chinese institutions in two years.The primary endpoint is 3-year relapse-free survival.The secondary endpoints are 5-year overall survival,proportion of patients who complete the postoperative chemotherapy and incidence of adverse events.Ethic and dissemination:The trial has been approved by the institutional review board of each participating institution and it was activated on December,2016.The enrollment will be finished in December,2018.Patient’s follow-up will be ended until December,2023.Trial registration:Clinical Trials.gov,identifier:NCT02867839.Registered on August 4,2016. | Xiang Hu Lin Chen Yian Du Biao Fan Zhaode Bu Xin Wang Yingjiang Ye Zhongtao Zhang Gang Xiao Fei Li Qingsi He Guoli Li Xian Shen Bin Xiong Liming Zhu Jiwei Liui Lian Liu Tao Wu Jing Zhou Jun Zhang Gang Zhao Xulin Wang Pin Liang Xinxin Wang Yan Zhang Xiaojiang Wu Ji Zhang Xin Ji Xianglong Zong Tao Fu Ziyu Jia Jiafu Ji | 2017 | Chinese Journal of Cancer Research2017，29，2： | 5 |
您所在的机构暂未开通此部分的功能，请联系管理员